Neuroendocrine carcinoma
Literature review and presentation of 20 cases
DOI:
https://doi.org/10.35954/SM1998.20.1.6Keywords:
Neuroendocrine carcinomas, carcinoids, non lung oat-cellAbstract
The neuroendocrine neoplasias have their origin in the neuroendocrine system, widely located which is derivation of the neural crest. It is classified in: group 1 or epithelial (neuroendocrine carcinomas) and group 2 or neural. A literature review is perfomed. Evolution and treatment of 20 cases of neuroendocrine carcinomas are presented. Both end points of the biology and clinical evolution are represented by the lung and apendicular carcinoid with a very indolent up-come and the very agressive oat cell carcinoma.
Twelve were female and 8 males. Mean age: 51 years (14-72). Three patients developed carcinoid syndrome (diarrhea, flushing and diarrhea 1). One patient with an ovarian neuroendocrine tumour developed a Cushing’s syndrome. Five presented increased urinary excretion of 5 HIAA. In the digestive tract were originated 8 carcinoids, 2 neuroendocrine carcinomas and 4 esophageal oat cell carcinomas. The others were: 1 lung carcinoid, 1 mucosecretant carcinoid of the breast, 1 neuroendocrine carcinoma of the ovary and 2 carcinoids and 1 oat cell of unknown primary.
Downloads
Metrics
References
(1) FEYRTER F. Carcinoid and carcinoma. Ergebn Allg Pathol 1934; 29: 305-489.
(2) PEARSE AGE. The cytochemestry and ultrastructure of polypeptide hormone producing cells of the APUD series and the embryologic, and physiologic of the concept. J HistocCytochem 1969; 17: 303.
(3) WICK MARK K. Neuroendocrine Neoplasia: An overvierw of current concept and terminology. American Society of Clinical Oncology, 30th. Annual Meeting. Educational Book 1994, 246-248.
(4) HALLER DG. Carcinoid and islet cell tumors of the gastrointestinal tract. Chapter 33, p. 449-460. En Gastrointestinal Oncology. Ahlgren JD, Mac Donald JS. JB Lippincott Company. Philadelphia. USA 1992.
(5) MOERTEL CG. An odyssey in the land of small tumors. J Clin Oncol 1987; 1503-1522.
(6) Oberg K, Erikson B. Medical treatment of Neuroendocrine gut and pancreatic tumors. Acta Oncol 1989; 28: 425-431.
(7) BRENNAN F, MAC DONALD JS. Carcinoid tumors. Chapter 35. En Cancer. Principios y Práctica de Oncología. De Vitta V, Hellman S. Barcelona. Salvat 1987.
(8) LARSON C, SHOGSEID B, OBERG K. Men-1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.
(9) SOGA J, TAZAWA K. Pathology analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 1971; 28: 990-998.
(10) CARNEY JA, GO VLW, FAIRBANKS VF, MOORE SB. The syndrome of gastric argyrophill carcinoid tumors and non antral gastric atrophy. Ann Intern Med 1983; 99: 761-766.
(11) BORCH K, RENVALL H, LIEDBERG G. Gastric endocrine cell hiperplasia and carcinoid tumors in Pernicious Anemia. Gastroenterol 1985; 88: 638- 648.
(12) ITSUNO M, WATANABE H, IWAFUCHI M, ITO S. Multiple carcinoids and endocrine cell micronets in type A gastritis. Cancer 1989; 63: 881-890.
(13) BORDI C, YU JY, BAGGI MT, DAVOLI C, PILATO FP. Gastric carcinoids and their precursor lesions. A histologic and inmunohistochemical study of 23 cases. Cancer 1991; 67: 663-672.
(14) RINDI G, LUINETTI O, CORNAGGIA M, CAPELLA C, SOLCIA E. Three subtypes of Gastric Argyrophill Carcinoid and the Gastric Neuroendocrine Carcinoma: A Clinicopathology study. Gastroenterol 1993; 104: 994-1006.
(15) CARISON HE, LOWITZ BB, CASCIATO DD. Tumores Endócrinos. En Manual de Oncología Clínica, 2da. Edición. Salvat 1990, p. 278-283.
(16) COTRAN RS, KUMAR V, ROBBINS SL. Robbins Pathology Basis of Disease. Philadelphia, WB Sanders, 1989.
(17) AJANI JA, CARRASCO H, SAMAAN NA. Therapeutic options in patients with advanced islet cell and carcinoids tumors. Reg Cancer Treat 1991; 3: 235-242.
(18) MOERTEL CG. Treatment of Carcinoids Tumors and the malignant Carcinoid Syndrome. J Clin Oncol 1983; 1: 727-740.
(19) LAMBERTS SW, BAKKER WH, REUBI JC. Somastotatin receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 23: 1246- 1249.
(20) NORTON JA, DOPPMANN JL, VENSEN RT. Curative resection in Zollinger-Ellison Syndrome: Results of a 10 years prospective study. Ann Surg 1992; 215: 8-18.
(21) LEGHA SS, VALDIVIESO M, NELSON RS. Chemotherapy for metastatic carcinoids tumors with Interferon not as suggested ?. Cancer 1991; 67: 547-549.
(22) MOERTEL CG, KVOLS LK, O’CONNELL MJ. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasm. Cancer 1991; 68: 227-232.
(23) KVOLS LK, MOERTEL CG, O’CONNELL MJ. Treatment of the malignant carcinoid syndrome: Evaluation of a long acting somastotatin analogue. N Engl J Med 1986; 315: 663-666.
(24) WYNICH D, BLOOM SR. Clinical Review: The use of the long acting somastotatin analog Octreatide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 1991; 73: 1-3.
(25) REUBI JC, KOALS LK, WASER B. Detection of somastotatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50: 5969-5972.
(26) OBERG K, FUNA K, ALM G. Effects of Leucocyte interferon on clinical symtoms and hormonal levels in patients with midgut carcinoid tumors and the carcinoid syndrome. N Engl J Med 1983; 309: 129- 133.
(27) VALIRNAK M, JARVINEN H, SALMELLA P. Is the treatment of metastatic carcinoid tumor with interferon not as suggested?. Cancer 1991; 67:547-591.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
